Cargando…

New Insights on the Progesterone (P4) and PGRMC1/NENF Complex Interactions in Colorectal Cancer Progression

SIMPLE SUMMARY: Progesterone (P4) via PGRMC1/NENF may stimulate the proliferation and invasion of colorectal cancer DLD-1 and HT-29 cells. PGRMC1 inhibition abolishes the effect of P4, suggesting that P4 in advanced colorectal cancer may act primarily through PGRMC1. Our data may provide the novel i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamińska, Joanna, Koper-Lenkiewicz, Olga Martyna, Ponikwicka-Tyszko, Donata, Lebiedzińska, Weronika, Palak, Ewelina, Sztachelska, Maria, Bernaczyk, Piotr, Dorf, Justyna, Guzińska-Ustymowicz, Katarzyna, Zaręba, Konrad, Wołczyński, Sławomir, Rahman, Nafis Ahmed, Dymicka-Piekarska, Violetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605590/
https://www.ncbi.nlm.nih.gov/pubmed/37894441
http://dx.doi.org/10.3390/cancers15205074
Descripción
Sumario:SIMPLE SUMMARY: Progesterone (P4) via PGRMC1/NENF may stimulate the proliferation and invasion of colorectal cancer DLD-1 and HT-29 cells. PGRMC1 inhibition abolishes the effect of P4, suggesting that P4 in advanced colorectal cancer may act primarily through PGRMC1. Our data may provide the novel insights into the action of P4, PGRMC1, and NENF in colorectal cancer. It seems that PGRMC1 and NENF may interact as possible cofactors in non-classical P4 signaling. Targeting the PGRMC1/NENF complex may open-up new therapeutic possibilities for patients with advanced colorectal cancer. Therefore, future studies aimed at developing treatment strategies for colorectal cancer could consider simultaneous PGRMC1 inhibition along with a blockage of NENF production and secretion. ABSTRACT: The literature data regarding the risk of colorectal cancer (CRC) in the context of hormone therapy (HT), including both estrogen–progestogen combinations and estrogen alone, are inconclusive. The precise relationship underlying the action of progesterone (P4) and progesterone receptors in CRC has yet to be determined. We characterized the expression profiles of both nuclear and membrane progesterone receptors and their potential cofactors in CRC tissues. Additionally, we analyzed the P4 and NENF treatment effects on the cell proliferation and invasion of DLD-1 and HT-29 colorectal cancer cells. We observed a weak expression of the nuclear P4 receptor (PGR), but an abundant expression of the P4 receptor membrane component 1 (PGRMC1) and neuron-derived neurotrophic factor (NENF) in the CRC tissues. P4 treatment stimulated the proliferation of the DLD-1 and HT-29 CRC cells. The co-treatment of P4 and NENF significantly increased the invasiveness of the DLD-1 and HT-29 cells. A functional analysis revealed that these effects were dependent on PGRMC1. AN immunocytochemical analysis demonstrated a cytoplasmic co-localization of PGRMC1 and NENF in the CRC cells. Moreover, the concentration of serum NENF was significantly higher in CRC patients, and P4 treatment significantly increased the release of NENF in the DLD-1 cells. P4 or NENF treatment also significantly increased the IL-8 release in the DLD-1 cells. Our data may provide novel insights into the action of P4 and PGRMC1/NENF in CRC progression, where NENF may act as a potential PGRMC1 co-activator in non-classical P4 signaling. Furthermore, NENF, as a secreted protein, potentially could serve as a promising circulating biomarker candidate for distinguishing between colorectal cancer patients and healthy individuals, although large-scale extensive studies are needed to establish this.